{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:09:49Z","timestamp":1792440589864,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41397-019-0108-y","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T12:49:13Z","timestamp":1571143753000},"page":"192-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2862-5681","authenticated-orcid":false,"given":"Dorothea","family":"Lesche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Everall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Pantelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad A.","family":"Bousman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"108_CR1","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.5694\/j.1326-5377.2003.tb05310.x","volume":"178","author":"C Pantelis","year":"2003","unstructured":"Pantelis C, Lambert TJ. Managing patients with \u201ctreatment-resistant\u201d schizophrenia. Med J Aust. 2003;178:S62\u20136.","journal-title":"Med J Aust"},{"key":"108_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441\u20139.","journal-title":"Am J Psychiatry"},{"key":"108_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-14-102","volume":"14","author":"S Warnez","year":"2014","unstructured":"Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14:102.","journal-title":"BMC Psychiatry"},{"key":"108_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s002130050028","volume":"148","author":"E Spina","year":"2000","unstructured":"Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia AG, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacol (Berl). 2000;148:83\u20139.","journal-title":"Psychopharmacol (Berl)"},{"key":"108_CR5","unstructured":"Freudenreich O, McEvoy J Guidelines for prescribing clozapine in schizophrenia. Waltham, MA 2018."},{"key":"108_CR6","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.pharep.2016.06.016","volume":"68","author":"J Piwowarska","year":"2016","unstructured":"Piwowarska J, Radziwon-Zaleska M, Dmochowska M, Szepietowska E, Matsumoto H, Sygitowicz G, et al. The usefulness of monitored therapy using Clozapine concentration in the blood serum for determining drug dose in Polish schizophrenic patients. Pharm Rep. 2016;68:1120\u20135.","journal-title":"Pharm Rep"},{"key":"108_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9\u201362.","journal-title":"Pharmacopsychiatry"},{"key":"108_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1124\/dmd.112.050484","volume":"41","author":"S Dragovic","year":"2013","unstructured":"Dragovic S, Gunness P, Ingelman-Sundberg M, Vermeulen NP, Commandeur JN. Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab Dispos. 2013;41:651\u20138.","journal-title":"Drug Metab Dispos"},{"key":"108_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","volume":"29","author":"E Jaquenoud Sirot","year":"2009","unstructured":"Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 2009;29:319\u201326.","journal-title":"J Clin Psychopharmacol"},{"key":"108_CR10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2217\/pgs.14.50","volume":"15","author":"MD Brennan","year":"2014","unstructured":"Brennan MD. Pharmacogenetics of second-generation antipsychotics. Pharmacogenomics. 2014;15:869\u201384.","journal-title":"Pharmacogenomics"},{"key":"108_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/JCP.0b013e31825ac35c","volume":"32","author":"ST Lee","year":"2012","unstructured":"Lee ST, Ryu S, Kim SR, Kim MJ, Kim S, Kim JW, et al. Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J Clin Psychopharmacol. 2012;32:441\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"108_CR12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.31887\/DCNS.2014.16.4\/jpouget","volume":"16","author":"JG Pouget","year":"2014","unstructured":"Pouget JG, Shams TA, Tiwari AK, Muller DJ. Pharmacogenetics and outcome with antipsychotic drugs. Dialogues Clin Neurosci. 2014;16:555\u201366.","journal-title":"Dialogues Clin Neurosci"},{"key":"108_CR13","doi-asserted-by":"publisher","first-page":"614","DOI":"10.4088\/JCP.12m07807","volume":"74","author":"SH Preskorn","year":"2013","unstructured":"Preskorn SH, Kane CP, Lobello K, Nichols AI, Fayyad R, Buckley G, et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry. 2013;74:614\u201321.","journal-title":"J Clin Psychiatry"},{"key":"108_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bcp.12441","volume":"79","author":"RR Shah","year":"2015","unstructured":"Shah RR, Smith RL. Addressing phenoconversion: the Achilles\u2019 heel of personalized medicine. Br J Clin Pharm. 2015;79:222\u201340.","journal-title":"Br J Clin Pharm"},{"key":"108_CR15","doi-asserted-by":"crossref","unstructured":"Mostafa S, Kirkpatrick CMJ, Byron K, Sheffield L An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes. J Neural Transm (Vienna). 2018;8\u201315.","DOI":"10.1007\/s00702-018-1922-0"},{"key":"108_CR16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1600-0773.1999.tb02016.x","volume":"85","author":"NH Seppala","year":"1999","unstructured":"Seppala NH, Leinonen EV, Lehtonen ML, Kivisto KT. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharm Toxicol. 1999;85:244\u20136.","journal-title":"Pharm Toxicol"},{"key":"108_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/00004714-200112000-00005","volume":"21","author":"JM Meyer","year":"2001","unstructured":"Meyer JM. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol. 2001;21:569\u201374.","journal-title":"J Clin Psychopharmacol"},{"key":"108_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","volume":"25","author":"TRE Barnes","year":"2011","unstructured":"Barnes TRE, Paton C. Antipsychotic polypharmacy in schizophrenia. CNS Drugs. 2011;25:383\u201399.","journal-title":"CNS Drugs"},{"key":"108_CR19","volume-title":"Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV)","author":"MB First","year":"1996","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV). Washington, D.C.: American Psychiatric Press, Inc; 1996."},{"issue":"Suppl 20","key":"108_CR20","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22\u201333. quiz 4-57","journal-title":"J Clin Psychiatry"},{"key":"108_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"key":"108_CR22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association.","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"108_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-017-0041-2","volume":"7","author":"MS Mostaid","year":"2017","unstructured":"Mostaid MS, Lee TT, Chana G, Sundram S, Shannon Weickert C, Pantelis C, et al. Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients. Transl Psychiatry. 2017;7:1280.","journal-title":"Transl Psychiatry"},{"issue":"4 Suppl","key":"108_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1359786806066041","volume":"20","author":"MA Enoch","year":"2006","unstructured":"Enoch MA, Shen PH, Xu K, Hodgkinson C, Goldman D. Using ancestry-informative markers to define populations and detect population stratification. J Psychopharmacol. 2006;20(4 Suppl):19\u201326.","journal-title":"J Psychopharmacol"},{"key":"108_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharm Ther. 2008;83:234\u201342.","journal-title":"Clin Pharm Ther"},{"key":"108_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2174\/1389200215666140202215316","volume":"15","author":"JK Hicks","year":"2014","unstructured":"Hicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr Drug Metab. 2014;15:218\u201332.","journal-title":"Curr Drug Metab"},{"key":"108_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FPC.0b013e328340bc5a","volume":"21","author":"DA Mrazek","year":"2011","unstructured":"Mrazek DA, Biernacka JM, O\u2019Kane DJ, Black JL, Cunningham JM, Drews MS, et al. CYP2C19 variation and citalopram response. Pharmacogenet Genomics. 2011;21:1\u20139.","journal-title":"Pharmacogenet Genomics"},{"key":"108_CR28","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/0269881119827959","volume":"33","author":"M Saiz-Rodr\u00edguez","year":"2019","unstructured":"Saiz-Rodr\u00edguez M, Ochoa D, Belmonte C, Rom\u00e1n M, Vieira de Lara D, Zubiaur P, et al. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics. J Psychopharmacol. 2019;33:522\u201331.","journal-title":"J Psychopharmacol"},{"key":"108_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s002280050163","volume":"51","author":"U Jeppesen","year":"1996","unstructured":"Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Br\u00f8sen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharm. 1996;51:73\u20138.","journal-title":"Eur J Clin Pharm"},{"key":"108_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/00004714-200104000-00007","volume":"21","author":"AT Harvey","year":"2001","unstructured":"Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol. 2001;21:161\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"108_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/00004714-200702000-00005","volume":"27","author":"SH Preskorn","year":"2007","unstructured":"Preskorn SH, Greenblatt DJ, Flockhart D, Luo Y, Perloff ES, Harmatz JS, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol. 2007;27:28\u201334.","journal-title":"J Clin Psychopharmacol"},{"key":"108_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1124\/jpet.115.225680","volume":"354","author":"M Klieber","year":"2015","unstructured":"Klieber M, Oberacher H, Hofstaetter S, Beer B, Neururer M, Amann A, et al. CYP2C19 phenoconversion by routinely prescribed proton pump inhibitors omeprazole and esomeprazole: clinical implications for personalized medicine. J Pharm Exp Ther. 2015;354:426\u201330.","journal-title":"J Pharm Exp Ther"},{"key":"108_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1365-2125.2001.01328.x","volume":"51","author":"S H\u00e4gg","year":"2001","unstructured":"H\u00e4gg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharm. 2001;51:169\u201373.","journal-title":"Br J Clin Pharm"},{"key":"108_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/clpt.2011.70","volume":"90","author":"M Dobrinas","year":"2011","unstructured":"Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharm Ther. 2011;90:117\u201325.","journal-title":"Clin Pharm Ther"},{"key":"108_CR35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat SocietySeries B (Methodol). 1995;57:289\u2013300.","journal-title":"J R Stat SocietySeries B (Methodol)"},{"key":"108_CR36","unstructured":"Jamovi. The jamovi project. Version 0.9. Jamovi. https:\/\/www.jamovi.org ; 2019."},{"key":"108_CR37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1755-0998.2010.02847.x","volume":"10","author":"L Excoffier","year":"2010","unstructured":"Excoffier L, Lischer HE. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour. 2010;10:564\u20137.","journal-title":"Mol Ecol Resour"},{"key":"108_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/0706743716670128","volume":"62","author":"K Vasudev","year":"2017","unstructured":"Vasudev K, Choi YH, Norman R, Kim RB, Schwarz UI. Genetic determinants of clozapine-induced metabolic side effects. Can J Psychiatry. 2017;62:138\u201349.","journal-title":"Can J Psychiatry"},{"key":"108_CR39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/PRA.0000000000000223","volume":"23","author":"M Wici\u0144ski","year":"2017","unstructured":"Wici\u0144ski M, W\u0119clewicz MM, Mi\u0119tkiewicz M, Malinowski B, Grze\u015bk E, Klonowska J. Potential mechanisms of hematological adverse drug reactions in patients receiving clozapine in combination with proton pump inhibitors. J Psychiatr Pract. 2017;23:114\u201320.","journal-title":"J Psychiatr Pract"},{"key":"108_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1600-0447.2012.01920.x","volume":"127","author":"M van Veggel","year":"2013","unstructured":"van Veggel M, Olofinjana O, Davies G, Taylor D. Clozapine and gastro-oesophageal reflux disease (GORD) - an investigation of temporal association. Acta Psychiatr Scand. 2013;127:69\u201377.","journal-title":"Acta Psychiatr Scand"},{"key":"108_CR41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/15622975.2017.1347712","volume":"18","author":"I Piatkov","year":"2017","unstructured":"Piatkov I, Caetano D, Assur Y, Lau SL, Coelho M, Jones T, et al. CYP2C19*17 protects against metabolic complications of clozapine treatment. World J Biol Psychiatry. 2017;18:521\u20137.","journal-title":"World J Biol Psychiatry"},{"key":"108_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1055\/s-0034-1371866","volume":"47","author":"FJ Diaz","year":"2014","unstructured":"Diaz FJ, Eap CB, Ansermot N, Crettol S, Spina E, de Leon J. Can valproic acid be an inducer of clozapine metabolism? Pharmacopsychiatry. 2014;47:89\u201396.","journal-title":"Pharmacopsychiatry"},{"key":"108_CR43","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0006-3223(94)90647-5","volume":"36","author":"P Finley","year":"1994","unstructured":"Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry. 1994;36:487\u20138.","journal-title":"Biol Psychiatry"},{"key":"108_CR44","first-page":"650","volume":"152","author":"LP Longo","year":"1995","unstructured":"Longo LP, Salzman C. Valproic acid effects on serum concentrations of clozapine and norclozapine. Am J Psychiatry. 1995;152:650.","journal-title":"Am J Psychiatry"},{"key":"108_CR45","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","volume":"24","author":"A Rostami-Hodjegan","year":"2004","unstructured":"Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24:70\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"108_CR46","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/FTD.0b013e3181dad1fb","volume":"32","author":"L Couchman","year":"2010","unstructured":"Couchman L, Morgan PE, Spencer EP, Flanagan RJ. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther Drug Monit. 2010;32:438\u201347.","journal-title":"Ther Drug Monit"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0108-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0108-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0108-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T01:17:35Z","timestamp":1721870255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-019-0108-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["108"],"URL":"https:\/\/doi.org\/10.1038\/s41397-019-0108-y","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"21 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SM is an employee of myDNA Inc., a company that provides pharmacogenetic testing. CP has participated on Advisory Boards for Janssen-Cilag, Astra-Zeneca, Lundbeck, and Servier. He has received honoraria for talks presented at educational meetings organized by Astra-Zeneca, Janssen-Cilag, Eli-Lilly, Pfizer, Lundbeck, and Shire. CAB is a member of Clinical Pharmacogenetics Implementation Consortium and the Genetic Testing Committee of the International Society of Psychiatric Genetics. He has also received material support from Assurex, CNSDose, Genomind, and AB-Biotics for research purposes and has ongoing research collaborations with MyDNA but does not have equity, stocks, or options in these companies or any other pharmacogenetic companies. The other authors of this manuscript have no relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}